RIDGEFIELD, Conn. and INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two new pooled analyses of phase III data with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, presented at the American Association of Clinical Endocrinologists (AACE) 22nd Annual Scientific & Clinical Congress.
In one retrospective pooled analysis, data were included from Hispanic/Latino adults with type 2 diabetes (T2D), a population that is disproportionately affected by T2D.1 Data pooled from six phase III studies showed that treatment with linagliptin reduced glucose levels (HbA1c) versus placebo in this patient population.
In a second retrospective analysis, data were pooled from two phase III studies that included people with long-standing T2D (>/=10 years). The analysis showed reductions in HbA1c from baseline with linagliptin versus placebo.
"Response to treatment can vary between sub-populations of adults with type 2 diabetes," said Christophe Arbet-Engels , MD, PhD, vice president, clinical development and medical affairs metabolic, Boehringer Ingelheim Pharmaceuticals, Inc. "Those with long-standing type 2 diabetes or of Hispanic/Latino origin are often difficult to treat or under-treated."
About Poster No. 1118 - Sub-population of Hispanic/Latino Adults with T2D
The findings from the first presentation were derived from six randomized, double-blind, placebo-controlled phase III studies of linagliptin 5 mg/d given as monotherapy or in addition to common glucose-lowering therapies.1 Of the six studies included in the analysis, two were 18 weeks in duration and four were 24 weeks in duration.1
SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
2. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
3. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
4. New Interim Analysis From Observational Study Suggests That Delivery Of Insulin Via Valeritas V-Go Shows Promise In Improving Glycemic Control For Patients With Type 2 Diabetes
5. Pharmacy Automation Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
6. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
7. Small Animal Imaging (In Vivo) Market - By systems and reagents - Competitive Analysis & Global Forecasts to 2017
8. 2013 BRIC Medical Devices Market & CIVETS Medical Equipment Industry Analysis
9. 2013 Cancer Diagnostics Market Analysis: Cancer Testing Industry Growing Rapidly
10. Antibody Technologies and Attrition Rates - An Industry Analysis 2013
11. Medical Equipment Monthly Deals Analysis: February 2013 - M&A and Investment Trends